John Wilcox

Has grant

Co-Founder & Chief Executive Officer

Country flagUnited States

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

John Wilcox is the Co-Founder and Chief Executive Officer of Diatech Diabetes, Inc. in the United States. His research areas focus on real-time monitoring and detection in diabetes management, particularly related to infusion failures. His recent articles include developments in algorithms for infusion failure detection and analyses of insulin infusion site failure in online communities for Type 1 diabetes.

Recent Grants

Grant: Close

SmartFusion(TM): A Novel Fluid Pressure Based Infusion Failure Detection System

Open Date: 2023-06-01

Close Date: 2026-06-01

Grant: Close

Development of a Personalized Infusion Failure Detection Algorithm combining Tissue Counter Pressure and Blood Glucose Data for Closed-loop Diabetes Management

Open Date: 2021-09-01

Close Date: 2022-12-01

Articles (3)

Background: Continuous subcutaneous insulin infusion (CSII) is a common treatment option for people with diabetes (PWD), but insulin infusion failures pose a significant challenge, leading to hyperglycemia, diabetes burnout, and increased hospitalizations. Current CSII pumps’ occlusion alarm systems are limited in detecting infusion failures; therefore, a more effective detection method is needed. Methods: We conducted five preclinical animal studies to collect data on infusion failures, utilizing both insulin and non-insulin boluses. Data were captured using in-line pressure and flow rate sensors, with additional force data from CSII pumps’ onboard sensors in one study. A novel classifier model was developed using this dataset, aimed at detecting different types of infusion failures through direct utilization of force sensor data. Performance was compared against various occlusion alarm thresholds from commercially available CSII pumps. Results: The testing dataset included 251 boluses. The Bagging classifier model showed the highest performance metrics among the models tested, exhibiting high accuracy (96%), sensitivity (94%), and specificity (98%), with lower false-positive and false-negative rate compared with traditional occlusion alarm pressure thresholds. Conclusions: Our study developed a novel non-threshold classifier that outperforms current occlusion alarm systems in CSII pumps in detecting infusion failures. This advancement has the potential to reduce the risk of hyperglycemia and hospitalizations due to undetected infusion failures, offering a more reliable and effective CSII therapy for PWD. Further studies involving human participants are recommended to validate these findings and assess the classifier’s performance in a real-world setting.

Year:

2024

Year:

2023

Year:

2023

Collaborators (5)

Michael Hughes

Assistant Professor of Medicine

Emory University

UNITED STATES
View details

Juan Carlos Espinoza Salomon

Associate Professor

Lurie Children's Hospital

UNITED STATES
View details

John Clark Gray

Chief Scientific Officer

-

UNITED STATES
View details

Luis Ernesto Blanco

Chief Technology Officer

-

UNITED STATES
View details

Rayhan A. Lal

Stanford University

UNITED STATES
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.